We try not to give investment advice about AXIM. Probably most people who post here on the AXIM IHUB board have been invested in AXIM since the Covid days.
AXIM is generating revenue right now. Revenue seems to be growing every month. Apparently the CLIA Waiver Applications for the existing tests have not been submitted to the FDA yet. There is some type of process that needs to be followed to fill out the Waiver Application and also comparison studies with tests that are already have Approved CLIA Waivers. It is not a "simple" process. Is sounds like AXIM has not even started the process.
What does this mean for the business?
AXIM will have revenue grow at a slow pace until CLIA Waivers are submitted and approved.
AND/OR
AXIM could use the potential for a "Blockbuster" Parkinsons disease Tear based Point-of-Care test to generate both Up-front and residual revenue by signing a Marketing agreement with a large Pharma that can take the full responsibility of walking the test through the FDA process with the agreement that AXIM would still receive a fixed amount per test after it goes to market. That could happen.
A lot of things could happen over the next few months. Interesting times for AXIM right now.
News 
Market Data 
Discover 
AI
